PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 59 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $321,325 | -39.5% | 30,986 | -16.4% | 0.00% | -100.0% |
| Q2 2023 | $530,857 | +191.2% | 37,071 | +45.2% | 0.00% | – |
| Q1 2023 | $182,284 | -35.2% | 25,530 | +1.8% | 0.00% | – |
| Q4 2022 | $281,442 | +5.0% | 25,084 | +3.6% | 0.00% | – |
| Q3 2022 | $268,000 | +27.6% | 24,220 | -2.8% | 0.00% | – |
| Q2 2022 | $210,000 | -25.3% | 24,930 | +20.9% | 0.00% | – |
| Q1 2022 | $281,000 | -37.4% | 20,625 | -9.7% | 0.00% | -100.0% |
| Q4 2021 | $449,000 | -37.7% | 22,849 | +1.7% | 0.00% | 0.0% |
| Q3 2021 | $721,000 | -23.8% | 22,473 | -19.6% | 0.00% | 0.0% |
| Q2 2021 | $946,000 | +44.2% | 27,938 | +60.0% | 0.00% | 0.0% |
| Q1 2021 | $656,000 | +21.9% | 17,463 | +7.8% | 0.00% | 0.0% |
| Q4 2020 | $538,000 | -11.8% | 16,194 | -2.6% | 0.00% | 0.0% |
| Q3 2020 | $610,000 | +11.5% | 16,629 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $547,000 | +27.5% | 16,629 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $429,000 | -16.2% | 16,629 | +1.2% | 0.00% | 0.0% |
| Q4 2019 | $512,000 | – | 16,437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |